Granted Patent B2

US 9,095,577 · App. 14/635,851 · Granted Aug 4, 2015

Abstract

Claims (74)

1. An edible film dosage composition consisting of:

a. ondansetron;

b. a polymeric carrier matrix consisting of:

i. hydroxypropylmethyl cellulose, and

ii. polyethylene oxide;

c. erythritol;

d. peppermint flavor;

e. calcium carbonate;

f. sucralose;

g. sodium bicarbonate;

h. fumed silica;

i. titanium dioxide;

j. monoammonium glycyrrhizinate;

k. xanthan gum; and

l. butylated hydroxytoluene.

2. The edible film dosage composition of claim 1 , wherein said polyethylene oxide is present in an amount of from about 20% to about 70% by weight and said hydroxypropylmethyl cellulose is present in an amount of from about 20% to about 70% by weight based on the total weight of the polymeric carrier matrix.

3. The edible film dosage composition of claim 1 , wherein said polyethylene oxide is present in an amount of from about 20% to about 60% by weight and said hydroxypropylmethyl cellulose is present in an amount of from about 20% to about 60% by weight based on the total weight of the polymeric carrier matrix.

4. The edible film dosage composition of claim 1 , wherein said titanium dioxide is present in an amount of from about 0.02 to about 3% by weight based on the total weight of the edible film dosage composition.

5. The edible film dosage composition of claim 1 , wherein said titanium dioxide is present in an amount of from about 0.02 to about 1% by weight based on the total weight of the edible film dosage composition.

6. An edible film dosage composition consisting of:

a. ondansetron;

b. a polymeric carrier matrix consisting of:

i. hydroxypropylmethyl cellulose;

c. erythritol;

d. peppermint flavor;

e. calcium carbonate;

f. sucralose;

g. sodium bicarbonate;

h. fumed silica;

i. titanium dioxide;

j. monoammonium glycyrrhizinate;

k. xanthan gum; and

l. butylated hydroxytoluene,

wherein the amount of monoammonium glycyrrhizinate is sufficient to prevent the strong electrophilic interaction of the alkyl chloride groups of the sucralose with the amine groups of the ondansetron and thereby prevent the agglomeration of the ondansetron and sucralose.

7. The edible film dosage composition of claim 6 , wherein said titanium dioxide is present in an amount of from about 0.02 to about 3% by weight based on the total weight of the edible film dosage composition.

8. The edible film dosage composition of claim 6 , wherein said titanium dioxide is present in an amount of from about 0.02 to about 1% by weight based on the total weight of the edible film dosage composition.

9. An edible film dosage composition consisting of:

a. ondansetron;

b. a polymeric carrier matrix consisting of:

i. hydroxypropylmethyl cellulose;

c. erythritol;

d. peppermint flavor;

e. calcium carbonate;

f. sucralose;

g. sodium bicarbonate;

h. fumed silica;

i. titanium dioxide;

j. monoammonium glycyrrhizinate;

k. xanthan gum; and

l. butylated hydroxytoluene,

wherein the amounts of ondansetron and monoammonium glycyrrhizinate are sufficient for the amines groups of the ondansetron to form an equilibrium with the ammonium ions of the monoammonium glycyrrhizinate.

10. The edible film dosage composition of claim 8 , wherein said titanium dioxide is present in an amount of from about 0.02 to about 3% by weight based on the total weight of the edible film dosage composition.

11. The edible film dosage composition of claim 8 , wherein said titanium dioxide is present in an amount of from about 0.02 to about 1% by weight based on the total weight of the edible film dosage composition.

12. An edible film dosage composition consisting of:

a. ondansetron;

b. a polymeric carrier matrix consisting of:

i. hydroxypropylmethyl cellulose, and

ii. polyethylene oxide;

c. erythritol;

d. peppermint flavor;

e. calcium carbonate;

f. sucralose;

g. sodium bicarbonate;

h. fumed silica;

i. titanium dioxide;

j. monoammonium glycyrrhizinate;

k. xanthan gum; and

l. butylated hydroxytoluene,

wherein the amount of monoammonium glycyrrhizinate is sufficient to prevent the strong electrophilic interaction of the alkyl chloride groups of the sucralose with the amine groups of the ondansetron and thereby prevent the agglomeration of the ondansetron and sucralose, and/or

wherein the amounts of ondansetron and monoammonium glycyrrhizinate are sufficient for the amines groups of the ondansetron to form an equilibrium with the ammonium ions of the monoammonium glycyrrhizinate.

13. The edible film dosage composition of claim 12 , wherein said polyethylene oxide is present in an amount of from about 20% to about 70% by weight and said hydroxypropylmethyl cellulose is present in an amount of from about 20% to about 70% by weight based on the total weight of the polymeric carrier matrix.

14. The edible film dosage composition of claim 12 , wherein said polyethylene oxide is present in an amount of from about 20% to about 60% by weight and said hydroxypropylmethyl cellulose is present in an amount of from about 20% to about 60% by weight based on the total weight of the polymeric carrier matrix.

15. The edible film dosage composition of claim 12 , wherein said titanium dioxide is present in an amount of from about 0.02 to about 3% by weight based on the total weight of the edible film dosage composition.

16. The edible film dosage composition of claim 12 , wherein said titanium dioxide is present in an amount of from about 0.02 to about 1% by weight based on the total weight of the edible film dosage composition.

Assignments (10)